Glivec shrink tumors but could also make them more aggressive and mobile
Posted 15 June 2012 - 06:19 AM
See also this article :
''Second cancers occur in a small percentage of patients receiving therapy with TKIs for hematologic malignancies, mostly CML. No evidence at the moment suggests that exposure to TKIs increases the risk of developing second cancers.'' Blood - October 2011
Posted 15 June 2012 - 06:42 AM
''In conclusion, CML-related deaths are uncommon in CML patients who are in CCyR two years after starting imatinib. Survival is not statistically significantly different from that of the general population. Side effects are present but generally not serious. A higher incidence of prostate cancer, to be confirmed and further analyzed, was observed''
Posted 15 June 2012 - 07:07 AM
Pericytes are found in Solid tumors, not Blood. There is no relationship to CML. Frank
Posted 15 June 2012 - 07:13 AM
The risk of secondary cancer was LESS than expected, including Prostate cancer. Frank
Posted 15 June 2012 - 11:41 PM
Well, since CML and prostate cancer is more often found in older individuals, likely there is no higher risk of getting prostate cancer than the general population. So, until it is investigated further, I would just forget about it.
Here is to your good heatlh and at least an average life span,
1 user(s) are reading this topic
0 members, 1 guests, 0 anonymous users